Humacyte, Inc.
ATEV
vascular injury
Resolved
583days ago
Approval decision · Dec 1, 2024
What's at stake
A final FDA approval decision on ATEV for vascular injury is expected Dec 1, 2024.
Primary source
· SEC 8-K
verified 14h ago
“Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular injury indication was approved by the FDA in December 2024.”